UBS Group
IART icon

UBS Group’s Integra LifeSciences IART Stock Holding History

UBS Group’s Portfolio IART Stock Details IART Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-55,000
Closed -$2.26M – 9677
2023
Q2 		$2.26M Sell
55,000
-53,000
-49% -$2.55M ﹤0.01% 3405
2023
Q1 		$6.2M Buy
+108,000
New +$6.09M ﹤0.01% 2314

Other funds holding IART

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
PCMI
Paradigm Capital Management Inc Albany, New York $2.61B AUM 78.58% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

UBS Group's IART Position: Q1 2026 in Review

UBS Group reduced its Integra LifeSciences (IART) stake by 50% in Q1 2026, selling an estimated $2.26M and leaving 202,745 shares worth $1.91M. The position accounts for ﹤0.01% of the portfolio, ranked #5016.

UBS Group first reported a position in IART in Q4 2014 and has held it in 46 quarters since. The position peaked at $5.08M in Q4 2025. 201 funds tracked by Wall St. Rank hold IART as of Q1 2026.

  • UBS Group held 202,745 shares of Integra LifeSciences worth $1.91M as of Q1 2026.
  • UBS Group sold 206,224 Integra LifeSciences shares in Q1 2026, an estimated $2.26M.
  • Integra LifeSciences made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #5016 holding.
  • UBS Group first reported a position in Integra LifeSciences in Q4 2014 and has held it in 46 quarters since.
  • UBS Group's Integra LifeSciences position peaked at $5.08M in Q4 2025.
  • 201 funds tracked by Wall St. Rank held Integra LifeSciences as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.